Caribou Biosciences | Evaluate

EHA 2022 preview – some good news at last

Positive data result in positive share price movements – something of a novelty in the current market.

AACR 2022 – the first biopharma catalysts emerge

October 05, 2021

Biotech listings show signs of a slowdown

2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.

February 16, 2017

Patent twists and turns make Crispr no easier to value

September 02, 2015

Crisp financing and partnering in gene editing space

January 29, 2015

CRISPR steps closer to centre stage as AstraZeneca piles in